WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer

Oncogene

Volumn 34, Issue 26, 2015, Pages 3452-3462

  King, M L ^a   Lindberg, M E ^a   Stodden, G R ^a   Okuda, H ^b   Ebers, S D ^a   Johnson, A ^c   Montag, A ^c   Lengyel, E ^c   Maclean Ii, J A ^a   Hayashi, K ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; FIBROBLAST GROWTH FACTOR 1; NICLOSAMIDE; WNT7A PROTEIN; WNT PROTEIN; WNT7A PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL FUNCTION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; EXON; FEMALE; GENE LOCUS; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL PROLIFERATION; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PHYSIOLOGY; WNT SIGNALING PATHWAY;

ANIMALS; BETA CATENIN; CELL PROLIFERATION; CELLS, CULTURED; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FIBROBLAST GROWTH FACTOR 1; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NICLOSAMIDE; OVARIAN NEOPLASMS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84933037846     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.277     Document Type: Article

References (54)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291: 2705-2712.
3. Teo R, Mohrlen F, Plickert G, Muller WA, Frank U. An evolutionary conserved role of Wnt signaling in stem cell fate decision. Dev Biol 2006; 289: 91-99.
4. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837-1851.
5. Liu W, Xing F, Iiizumi-Gairani M, Okuda H, Watabe M, Pai SK et al. N-myc downstream regulated gene 1 modulates Wnt-beta-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol Med 2012; 4: 93-108.
6. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17: 45-51.
7. Gatcliffe TA, Monk BJ, Planutis K, Holcombe RF. Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer 2008; 18: 954-962.
8. Arend RC, Londono-Joshi AI, Straughn JM Jr, Buchsbaum DJ. The Wnt/betacatenin pathway in ovarian cancer: a review. Gynecol Oncol 2013; 131: 772-779.
9. Yoshioka S, King ML, Ran S, Okuda H, MacLean JA 2nd, McAsey ME et al. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/ beta-catenin pathway. Mol Cancer Res 2012; 10: 469-482.
10. Friesel RE, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 1995; 9: 919-925.
11. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165-197.
12. Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 2007; 25: 2281-2287.
13. Meng QH, Xu E, Hildebrandt MA, Liang D, Lu K, Ye Y et al. Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome. Clin Chem 2014; 60: 222-232.
14. Smith G, Ng MT, Shepherd L, Herrington CS, Gourley C, Ferguson MJ et al. Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. Br J Cancer 2012; 107: 1327-1336.
15. Lu W, Lin C, Roberts MJ, Waud WR, Piazza GA, Li Y. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway. PLoS ONE 2011; 6: e29290.
16. Mook RA Jr, Chen M, Lu J, Barak LS, Lyerly HK, Chen W. Small molecule modulators of Wnt/beta-catenin signaling. Bioorg Med Chem Lett 2013; 23: 2187-2191.
17. Osada T, Chen M, Yang XY, Spasojevic I, Vandeusen JB, Hsu D et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res 2011; 71: 4172-4182.
18. Sack U, Walther W, Scudiero D, Selby M, Kobelt D, Lemm M et al. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst 2011; 103: 1018-1036.
19. Wieland A, Trageser D, Gogolok S, Reinartz R, Hofer H, Keller M et al. Anticancer effects of niclosamide in human glioblastoma. Clin Cancer Res 2013; 19: 4124-4136.
20. Chen M, Wang J, Lu J, Bond MC, Ren XR, Lyerly HK et al. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 2009; 48: 10267-10274.
21. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 2006; 66: 1354-1362.
22. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC. Current management strategies for ovarian cancer. Mayo Clin Proc 2007; 82: 751-770.
23. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
24. Chotani MA, Chiu IM. Differential regulation of human fibroblast growth factor 1 transcripts provides a distinct mechanism of cell-specific growth factor expression. Cell Growth Differ 1997; 8: 999-1013.
25. Madiai F, Hackshaw KV, Chiu IM. Characterization of the entire transcription unit of the mouse fibroblast growth factor 1 (FGF-1) gene. Tissue-specific expression of the FGF-1.A mRNA. J Biol Chem 1999; 274: 11937-11944.
26. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev 2006; 5: 997-1014.
27. Chen W, Chen M, Barak LS. Development of small molecules targeting the Wnt pathway for the treatment of colon cancer: a high-throughput screening approach. Am J Physiol Gastrointest Liver Physiol 2010; 299: G293-G300.
28. Dodge ME, Lum L. Drugging the cancer stem cell compartment: lessons learned from the hedgehog and Wnt signal transduction pathways. Annu Rev Pharmacol Toxicol 2011; 51: 289-310.
29. Meijer L, Flajolet M, Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 2004; 25: 471-480.
30. Steele IA, Edmondson RJ, Bulmer JN, Bolger BS, Leung HY, Davies BR. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene 2001; 20: 5878-5887.
31. Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN et al. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res 2013; 19: 809-820.
32. Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR, Varmus HE. FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J 2005; 24: 73-84.
33. Curtin JC, Lorenzi MV. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2010; 1: 563-577.
34. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009; 461: 614-620.
35. Yo YT, Lin YW, Wang YC, Balch C, Huang RL, Chan MW et al. Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther 2012; 11: 1703-1712.
36. Cooke PS, Spencer TE, Bartol FF, Hayashi K. Uterine glands: development, function and experimental model systems. Mol Hum Reprod 2013; 19: 547-558.
37. Sassoon D. Wnt genes and endocrine disruption of the female reproductive tract: a genetic approach. Mol Cell Endocrinol 1999; 158: 1-5.
38. Balgi AD, Fonseca BD, Donohue E, Tsang TC, Lajoie P, Proud CG et al. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS ONE 2009; 4: e7124.
39. Fonseca BD, Diering GH, Bidinosti MA, Dalal K, Alain T, Balgi AD et al. Structureactivity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem 2012; 287: 17530-17545.
40. Jin Y, Lu Z, Ding K, Li J, Du X, Chen C et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NFkappaB pathway and generation of reactive oxygen species. Cancer Res 2010; 70: 2516-2527.
41. Li R, Hu Z, Sun SY, Chen ZG, Owonikoko TK, Sica GL et al. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol Cancer Ther 2013; 12: 2200-2212.
42. You S, Li R, Park D, Xie M, Sica GL, Cao Y et al. Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer. Mol Cancer Ther 2014; 13: 606-616.
43. Kim NG, Koh E, Chen X, Gumbiner BM. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc Natl Acad Sci USA 2011; 108: 11930-11935.
44. Lau MT, Klausen C, Leung PC. E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via beta-catenin-Egr1-mediated PTEN expression. Oncogene 2011; 30: 2753-2766.
45. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998; 392: 190-193.
46. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993; 5: 806-811.
47. Hayashi K, Erikson DW, Tilford SA, Bany BM, Maclean JA 2nd, Rucker EB 3rd et al. Wnt genes in the mouse uterus: potential regulation of implantation. Biol Reprod 2009; 80: 989-1000.
48. Hayashi K, Burghardt RC, Bazer FW, Spencer TE. WNTs in the ovine uterus: potential regulation of periimplantation ovine conceptus development. Endocrinology 2007; 148: 3496-3506.
49. Chauhan SC, Vannatta K, Ebeling MC, Vinayek N, Watanabe A, Pandey KK et al. Expression and functions of transmembrane mucin MUC13 in ovarian cancer. Cancer Res 2009; 69: 765-774.
50. Singh AP, Moniaux N, Chauhan SC, Meza JL, Batra SK. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res 2004; 64: 622-630.
51. Maclean JA 2nd, Hu Z, Welborn JP, Song HW, Rao MK, Wayne CM et al. The RHOX homeodomain proteins regulate the expression of insulin and other metabolic regulators in the testis. J Biol Chem 2013; 288: 34809-34825.
52. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-5208.
53. Denkert C, Budczies J, Darb-Esfahani S, Gyorffy B, Sehouli J, Konsgen D et al. A prognostic gene expression index in ovarian cancer-validation across different independent data sets. J Pathol 2009; 218: 273-280.
54. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 2008; 68: 5478-5486.